Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors
The tone has changed dramatically since last year for LGBT rights groups, which are now as focused on opposing the Trump administration's policies as celebrating progress and community.
Drug prices, as you may have heard, are kind of high. But price growth has slowed after sharp spikes in 2014 and 2015.
Hepatitis C is so 2015 — at least, that's what Gilead Sciences CEO John Milligan is saying following his first year at the helm.
Is Pfizer finally in a position to close the Lipitor chapter, the one titled "how to bounce back from monumental loss"? All signs indicate yes.
After mulling over M&A options, Johnson & Johnson sprang into action in pursuit of Swiss biotech Actelion and initially received muted applause from investors.
The Kenilworth, New Jersey, company expects 2017 to produce the same worldwide sales scenario as last year. Yet despite the cautious outlook, stock prices are hovering higher than they were at this time in 2016.
Biotech major Amgen is making good on a lofty promise to generate $1.5 billion in savings by 2018.
The 2016 headliner for Teva Pharmaceutical Industries was its acquisition of Actavis Generics, which sent $33.43 billion in cash and about 100 million Teva shares to Allergan.
Any conversation about AbbVie has to begin with Humira, the best-selling drug in the world and the drugmaker's most important product.
Sanofi has been browsing in the acquisition aisle for some time now, even wheeling a few companies to the register only to leave empty-handed.
The FDA made patients, providers, and investors very happy when it approved Roche's Ocrevus in March.
Following one of the most anticipated exclusivity losses of the decade, sales of Novartis cancer drug Gleevec slipped 28% in 2016 to $3.3 billion.
Eli Lilly has faced a rough patch. Last November, the company took a $150 million charge over its failed high-profile Alzheimer's disease drug solanezumab.
AstraZeneca brought its internal overhaul A game in 2016, leaving investors humming the tune of a much-needed turning point.
FDA presents ideas to tackle drug prices; patients aware of side effects more likely to report them; scientists use Apple's Research Kit for clinical purposes
Brian Goff is expected to replace Carsten Thiel in June. The drugmaker said Tuesday that Thiel along with several other execs would be leaving the firm.
Recent grads aren't afraid to voice their expectations, and agencies are responding with new programs and policies.
FDA requires boxed warning for J&J's Invokana; Amazon to reportedly hire GM to enter pharmacy industry; WannCry ransomware affects some health organizations
A New York county sues drugmakers over opioid marketing; AstraZeneca files suit against GSK exec; Thermo Fisher acquires biologics firms
The deal will create one of the three biggest contract research organizations in the world.
Perhaps we should always bear in mind the need to periodically reinvigorate and reshape our careers.
The drugmaker's video asks people in New York and San Francisco about their ideas for great inventions.
Pacira also recently announced a partnership with Johnson & Johnson to co-promote its pain injection for certain surgeries.
Alexion names former Baxalta head as CEO; U.S. dollar drops after AHCA-fail; EMA advises suspension of 300 generic drugs by Indian drugmaker
P&G's Mark Chakravarty has joined pharma giant Novartis in a senior role.
Ten drugmakers seek to exclude pricing information from proxy ballots; roughly 85% of patient advocacy groups get industry funding; Juno halts lead CAR-T project
Novo Nordisk appoints new CEO, and more people moves for you to know about
The company acquired Everyday Health in December.
Teva CEO steps down; Mylan to pay $96.5 million to settle pay-for-delay claims; Merck files Keytruda with the FDA for bladder cancer